series-b
Stage
3
Investors
About
Curetis GmbH develops and provides the Unyvero A50, a rapid molecular diagnostic platform that identifies pathogens and resistance markers within 5 hours to support treatment decisions for severe infections.
Explore Curetis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.